Saturday, October 19, 2013
Tuesday, September 24, 2013
Saturday, September 21, 2013
Saturday, August 17, 2013
Wednesday, August 14, 2013
Tuesday, August 13, 2013
Monday, August 12, 2013
Friday, August 2, 2013
Wednesday, July 31, 2013
Saturday, July 27, 2013
Friday, July 26, 2013
Thursday, July 25, 2013
Monday, July 22, 2013
Saturday, July 20, 2013
Thursday, July 18, 2013
Wednesday, July 17, 2013
Tuesday, July 16, 2013
Monday, July 15, 2013
Sunday, July 14, 2013
Saturday, July 13, 2013
Thursday, July 11, 2013
Wednesday, July 10, 2013
Tuesday, July 9, 2013
Saturday, July 6, 2013
Thursday, July 4, 2013
Monday, July 1, 2013
Friday, June 28, 2013
MLN MATTERS
 | Subscriber’s Note: If you missed any of the MLN Matters® Articles notices as of June 2007, please review the archive available at: https://list.nih.gov/cgi-bin/wa.exe?A0=MLNMATTERS-L. |
Revised:
MM8056 – Payment Related to Prior Authorization for Power Mobility Devices (PMD)
MM8304 – Detailed Written Orders and Face-to-Face Encounters
Health Care updates: New AHRQ Web Page for Clinicians, Survey to Help A...
Health Care updates: New AHRQ Web Page for Clinicians, Survey to Help A...: New AHRQ Web Page for Clinicians, Survey to Help AHRQ Shape New Tools, and More!
MY FRIENDS AND NURSES, PLEASE KEEP UP WITH THIS BLOG TO KEEP YOU UP TO DATE!
MY FRIENDS AND NURSES, PLEASE KEEP UP WITH THIS BLOG TO KEEP YOU UP TO DATE!
Thursday, June 27, 2013
Wednesday, June 26, 2013
Tuesday, June 25, 2013
Health Care updates: Anxiety Update
Health Care updates: Anxiety Update: Anxiety Update
I'm getting a bad case of Anxiety because my Nurse friends are not reading this Blog. You must keep up to date and I have made it so easy. One Click and your here, but information from every where.
I'm getting a bad case of Anxiety because my Nurse friends are not reading this Blog. You must keep up to date and I have made it so easy. One Click and your here, but information from every where.
Sunday, June 23, 2013
Friday, June 21, 2013
Thursday, June 20, 2013
Wednesday, June 19, 2013
Tuesday, June 18, 2013
3 minute movie on ICD-10 transition
 |
| |||||||
| Big change brings big opportunities | ||||||||
 | ||||||||
 | ||||||||
| ||||||||
3 minute movie on ICD-10 transition
|
| |||||||
| Big change brings big opportunities | ||||||||
| ||||||||
| ||||||||
| ||||||||
Zyprexa injectable warning
 |
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The U.S. Food and Drug Administration (FDA) is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa Relprevv (olanzapine pamoate). The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Relprevv Risk Evaluation and Mitigation Strategy (REMS). Both patients were found to have very high olanzapine blood levels after death. High doses of olanzapine can cause delirium, cardiopulmonary arrest, cardiac arrhythmias, and reduced level of consciousness ranging from sedation to coma.
FDA is providing this information to health care professionals while it continues its investigation. If therapy with Zyprexa Relprevv is started or continued in patients, health care professionals should follow the REMS requirements and drug label recommendations. Patients and caregivers should talk to their health care professional(s) about any questions or concerns.
Under the REMS, patients are required to receive the Zyprexa Relprevv injection at a REMS-certified health care facility, to be continuously monitored at the facility for at least 3 hours following an injection, and to be accompanied home from the facility. The Zyprexa Relprevv label contains warnings about the risk of post-injection delirium sedation syndrome (PDSS), a serious condition in which the drug enters the blood too fast following an intramuscular injection, causing greatly elevated blood levels with marked sedation (possibly including coma) and/or delirium. In the clinical trials supporting the approval of Zyprexa Relprevv, cases of PDSS were observed within 3 hours after administration of Zyprexa Relprevv, but there were no deaths due to PDSS. These two patients died 3-4 days after receiving an appropriate dose of the drug, and it is not clear whether they died from PDSS.
At this time, FDA is continuing to evaluate these deaths and will provide an update when more information is available.
For more information please visit: Zyprexa Relprevv
Monday, June 17, 2013
CMS update
| The Coordination of Benefits and Medicare Secondary Payer Recovery sections on the Medicare tab of the CMS.Gov Web Site have been redesigned and restructured. As part of this restructuring, all pertinent information from the MSPRC.info web site has been incorporated into this new design and web page links have changed. Please visit the Coordination of Benefits & Recovery section of CMS.gov to see our new web pages. CMS provides the ability for you to be automatically notified when changes are made to the Coordination of Benefits & Recovery Overview web pages. If you have not already signed up for these notifications, please click the Subscription Sign-up Notification link found in the Related Links section of the web pages. When new information regarding Coordination of Benefits & Recovery are available, you will be notified. These announcements will also be posted to the What’s New page of the corresponding web pages. The following short-cuts have also been created for each of the new web pages: Attorney Services: http://go.cms.gov/attorney Beneficiary Services: http://go.cms.gov/bene COBA Trading Partners: http://go.cms.gov/cobatp Employer Services: http://go.cms.gov/employer Insurer Services: http://go.cms.gov/insurer Prescription Drug Assistance Programs: http://go.cms.gov/pdap Provider Services: http://go.cms.gov/provider Mandatory Insurer Reporting For Non Group Health Plan: http://go.cms.gov/mirnghp Workers’ Compensation Medicare Set-Aside Arrangements: http://go.cms.gov/wcmsa |
| Centers for Medicare & Medicaid Services (CMS) has sent this update. To contact Centers for Medicare & Medicaid Services (CMS) go to our contact us page. |
| This e-mail was sent to Dmcg1593@live.com using GovDelivery, on behalf of the Centers for Medicare & Medicaid Services (410-786-5473) · 7500 Security Boulevard · Baltimore MD 21244 |
This week in NIH Research Matters: A tool used to assess cardiovascular disease risk can gauge stroke risk, according to a large analysis. Even small improvements in lifestyle factors could help prevent strokes. A smoking-cessation medication can also help lower alcohol craving and dependence. The finding may lead to another treatment option for alcohol problems. Researchers identified brain circuits responsible for compulsive behaviors in mice. The findings could lead to new approaches for obsessive-compulsive disorder.
NIH Research Matters is on Facebook! Join us at www.facebook.com/ResearchMatters, and write on our wall. NIH Research Matters is also available as an RSS News Feed. Point your RSS reader to http://www.nih.gov/researchmatters/feed.xml (to learn more about RSS, visit http://www.nih.gov/news/rss.htm). Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact support@govdelivery.com. For all other inquiries about NIH programs and activities, please contact NIHinfo@od.nih.gov. Before writing, please view our Frequently Asked Questions page, our A-Z Health Topics page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®
|
Saturday, June 15, 2013
Friday, June 14, 2013
Google
 | Subscriber’s Note: If you missed any of the MLN Matters® Articles notices as of June 2007, please review the archive available at: https://list.nih.gov/cgi-bin/wa.exe?A0=MLNMATTERS-L. |
New:
MM8257 – Billing Social Work and Psychological Services in Comprehensive Outpatient Rehabilitation Facilities (CORFs)
MM8928 – Quarterly Update to the Correct Coding Initiative (CCI) Edits, Version 19.2, Effective July 1, 2013
Revised:
MM8213 – Autologous Platelet-Rich Plasma (PRP) for Chronic Non-Healing Wounds
MM8317 – July 2013 Integrated Outpatient Code Editor (I/OCE) Specifications Version 14.2
Your feedback is important to us as we use your suggestions to improve the quality of MLN Matters® articles so they better meet your educational needs. To provide feedback on MLN Matters® articles, we encourage you to submit your feedback online. Your participation is strictly anonymous, and it will only take a few minutes to complete.
You may also evaluate MLN Matters® articles, by visiting http://go.cms.gov/MLNMattersArticles and clicking on the ‘MLN Opinion Page’ link under ‘Related Links’. From that page, click on the ‘MLN Evaluations’ link under ‘Related Links’, and select ‘MLN Matters Articles’ from the list of products. After you have completed the evaluation, click on ‘Submit.’
DO NOT respond to this email. This list is used for one-way communication only and is NOT monitored. Please send any comments or questions related to MLN Matters® articles to MLN@cms.hhs.gov. CMS’ Privacy Policy is available at: http://www.cms.gov/About-CMS/Agency-Information/Aboutwebsite/Privacy-Policy.html. Information about the Freedom of Information Act (FOIA) is available at: http://www.cms.gov/About-CMS/Agency-Information/Aboutwebsite/FOIA.html.
Wednesday, June 12, 2013
  |
Warfarin 2 mg Tablets by Zydus Pharmaceuticals USA Inc.: Recall - Due to Oversized Tablet
06/12/2013
AUDIENCE: Pharmacy, Patient, Health Professional
ISSUE: Zydus Pharmaceuticals USA Inc. is voluntarily recalling one lot of Warfarin 2 mg Tablets, Lot #MM5767, expiration date June 2014 to the retail level. Four tablets of Warfarin 2 mg Tablets, Lot MM5767, have been found to be oversized in one product complaint.
Ingestion of a greater than intended dose of Warfarin, could lead to an increased pharmacological effect of warfarin. As a result, patients would be more likely to develop bleeding as an adverse reaction and in some patients that bleeding into a critical organ (mostly the central nervous system) could be fatal. The risk of bleeding is increased if overdosing is repeated continuously on a daily basis.
BACKGROUND: The product is used as prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE), prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement and reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Product is packaged in HDPE Bottle of 1000's count, which may have been dispensed to patients in smaller bottles. The only lot affected of Warfarin 2 mg Tablets being recalled is Lot MM5767.
The product can be identified by its NDC #6838205310. The product was distributed nationwide in the United States to wholesalers/distributors, retailers and mail order providers, from November 2012 to December 2012.
RECOMMENDATION: Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this particular lot of Warfarin 2 mg Tablets. Anyone with an existing inventory of this particular Lot MM5767 of Warfarin 2 mg Tablets should stop use and distribution, quarantine the recalled lots immediately and call INMAR at 1-800-967-5952 between the hours of 7 a.m. to 4 p.m. CST, Monday through Friday, to arrange for their return. In case patients have tablets of this lot of product, make sure all the tablets are of same size and if unsure, patients should consult their dispensing pharmacy.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Complete and submit the report Online: www.fda.gov/MedWatch/report.htm. Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
For Complete MedWatch Safety Alert including link to Firm Press Release: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm356519.htm
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Follow MedWatch on Twitter
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to dmcg1593@live.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
Monday, June 10, 2013
Subscribe to:
Posts (Atom)